Literature DB >> 15375376

Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.

Alexandra Stege1, Axel Priebsch, Christiane Nieth, Hermann Lage.   

Abstract

Multidrug resistance (MDR) is the major cause of failure of effective chemotherapeutic treatment of disseminated neoplasms. The "classical" MDR phenotype of human malignancies is mediated by drug extrusion by the adenosine triphosphate binding cassette (ABC)-transporter P-glycoprotein (MDR1/P-gp). For stable reversal of "classical" MDR by RNA interference (RNAi) technology, an H1-RNA gene promoter-driven expression vector encoding anti-MDR1/P-gp short hairpin RNA (shRNA) molecules was constructed. By introduction of anti-MDR1/P-gp shRNA expression vectors into the extremely high drug-resistant human gastric carcinoma cell line EPG85-257RDB, the MDR phenotype was completely reversed. The reversal of MDR was accompanied by a complete suppression of MDR1/P-gp expression on mRNA and protein level, and by a considerable increased intracellular anthracyline accumulation in the anti-MDR1/P-gp shRNA-treated cells. The data indicate that stable shRNA-mediated RNAi can be tremendously effective in reversing MDR1/P-gp-mediated MDR and is therefore a promising strategy for overcoming MDR by gene therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375376     DOI: 10.1038/sj.cgt.7700751

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  17 in total

Review 1.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

2.  Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.

Authors:  Tatsuaki Tagami; Takuya Suzuki; Kiyomi Hirose; Jose Mario Barichello; Naoshi Yamazaki; Tomohiro Asai; Naoto Oku; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

3.  Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.

Authors:  Zhilan Li; Xiudi Jiang; Peihong Chen; Xuebing Wu; Aihua Duan; Yiyu Qin
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

4.  Inhibition of P-glycoprotein over-expression by shRNA-mdr1b in rat astrocytes.

Authors:  Lei Chen; Xinwang Cheng; Linyu Tian; Tianhua Yang; Stefan Hermann; Dong Zhou
Journal:  Neurochem Res       Date:  2008-08-02       Impact factor: 3.996

5.  Effects of Livin gene RNA interference on apoptosis of cervical cancer HeLa cells and enhanced sensitivity to cisplatin.

Authors:  Lili Yu; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

6.  Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae.

Authors:  Erwin Lamping; Brian C Monk; Kyoko Niimi; Ann R Holmes; Sarah Tsao; Koichi Tanabe; Masakazu Niimi; Yoshimasa Uehara; Richard D Cannon
Journal:  Eukaryot Cell       Date:  2007-05-18

7.  Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy.

Authors:  João G Marques; Vítor M Gaspar; David Markl; Elisabete C Costa; Eugénia Gallardo; Ilídio J Correia
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

8.  Probing cholesterol binding and translocation in P-glycoprotein.

Authors:  Sundar Thangapandian; Karan Kapoor; Emad Tajkhorshid
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-10-30       Impact factor: 3.747

9.  Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25.

Authors:  Li Zhang; Ruijing Xiao; Jie Xiong; Jun Leng; Altaf Ehtisham; Yi Hu; Qianshan Ding; Hui Xu; Shengwu Liu; Jin Wang; Dean G Tang; Qiuping Zhang
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

10.  Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Authors:  S Darb-Esfahani; R Kronenwett; G von Minckwitz; C Denkert; M Gehrmann; A Rody; J Budczies; J C Brase; M K Mehta; H Bojar; B Ataseven; T Karn; E Weiss; D M Zahm; F Khandan; M Dietel; S Loibl
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.